Applied Physiology Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Neuroimmunomodulation. 2021;28(3):150-157. doi: 10.1159/000515595. Epub 2021 Jun 28.
In recent investigations addressing neurodegenerative diseases, especially multiple sclerosis (MS), the roles of brain-derived neurotrophic factor (BDNF) and interleukin-6 (IL-6) have been examined.
Forty-five relapsing-remitting MS (RRMS) patients, including 32 IFN-β-treated and 13 newly identified untreated cases as well as 45 sex- and age-matched healthy controls, were recruited in the study. Plasma levels of BDNF and IL-6 were assessed using the ELISA method. Data were analyzed by SPSS (ver.21).
There were significant differences between the case and healthy control groups in terms of the plasma levels of BDNF (p value = 0.044) and IL-6 (p value <0.001). Besides, the treatment with IFN-β had no significant impact on the level of BDNF or IL-6 in RRMS patients as compared to healthy controls (p value = 0.716 and 0.623 for BDNF and IL-6, respectively). Furthermore, the increase in the plasma levels of BDNF and IL-6 indicated a direct correlation in the case group (r = 0.508, p value = 0.008). In detail, following the classification of the case group into 2 subgroups of IFN-β-treated and untreated patients, a direct positive correlation was observed between the plasma levels of BDNF and IL-6 in IFN-β-treated patients (r = 0.495, p value = 0.026).
The IFN-β treatment seems not to be effective for upregulating BDNF and IL-6 in RRMS patients.
在最近针对神经退行性疾病（尤其是多发性硬化症）的研究中，研究了脑源性神经营养因子（BDNF）和白细胞介素-6（IL-6）的作用。
研究纳入了 45 名复发缓解型多发性硬化症（RRMS）患者，包括 32 名接受 IFN-β 治疗的患者和 13 名新确诊的未接受治疗的患者，以及 45 名性别和年龄匹配的健康对照者。采用 ELISA 法检测 BDNF 和 IL-6 的血浆水平。采用 SPSS（ver.21）对数据进行分析。
病例组与健康对照组的 BDNF（p 值=0.044）和 IL-6（p 值<0.001）血浆水平存在显著差异。此外，与健康对照组相比，RRMS 患者接受 IFN-β 治疗后，BDNF 或 IL-6 水平无显著变化（BDNF 和 IL-6 的 p 值分别为 0.716 和 0.623）。此外，病例组 BDNF 和 IL-6 血浆水平的升高呈直接正相关（r=0.508，p 值=0.008）。具体而言，根据病例组分为 IFN-β 治疗组和未治疗组，IFN-β 治疗组的 BDNF 和 IL-6 血浆水平呈直接正相关（r=0.495，p 值=0.026）。
IFN-β 治疗似乎不能上调 RRMS 患者的 BDNF 和 IL-6。
